Helix News and Research

RSS

Helix Hearing Care Centre and RA Centre host Healthy Aging Day

Helix Hearing Care Centre, The Senior Citizens Council of Ottawa, and the RA Centre hosted a Healthy Aging Day on Monday, where a capacity crowd of golden agers gathered to find out more about healthy hearing.

28 Oct 2009

Ohio State University researchers first to observe real-time behavior of the Dpo4 enzyme

Scientists here have identified how the motions of an enzyme are related to correctly copying genetic instructions, setting the stage for studies that can uncover what happens when DNA copying mistakes are made.

28 Oct 2009

Overview of Compugen’s DAC Blockers Platform presented at Fifth Peptide Engineering Meeting

Speaking today in Barcelona at the Fifth Peptide Engineering Meeting, Compugen Ltd. project manager Dr. Yossef Kliger provided an overview of Compugen’s DAC Blockers Platform and reviewed disease model data for selected product candidates.

26 Oct 2009

Helix Hearing Care Centre's initiative to increase hearing healthcare awareness

Helix Hearing Care Centre, a subsidiary of Lifestyle Hearing Corporation, has recently signed a sponsorship agreement with the Ottawa Senators. They are now the Official Hearing Care Company of one of Canada's most-loved hockey teams.

22 Oct 2009

Presentation on L-DOS47 drug formulation and development at Pharmaceutical Industry Conference

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: HXBPF) today announced that a presentation on L-DOS47 formulation and analytical method development will be made at the "Formulation Strategies for Protein Therapeutics" conference to be held on October 13 to 15, 2009, in Raleigh, North Carolina. The conference is sponsored by IBC Life Sciences.

14 Oct 2009

Helix BioPharma's pre-IND meetings with the FDA for Topical Interferon Alpha-2b and L-DOS47 fruitful

Helix BioPharma Corp. today announced progress updates for its ongoing Topical Interferon Alpha-2b and L-DOS47 product development programs following pre-investigational new drug ("pre-IND") meetings with the U.S. Food and Drug Administration ("FDA").

7 Oct 2009

Scientists uncover the role of first-responder molecule involved in repairing DNA strand breaks

Scientists from the U.S. Department of Energy's Lawrence Berkeley National Laboratory and the Scripps Research Institute have uncovered the role played by the least-understood part of a first-responder molecule that rushes in to bind and repair breaks in DNA strands, a process that helps people avoid cancer.

5 Oct 2009

E-18 Corp. enters dental syringe market, completes US patent filing for the Protectus Safety Dental Syringe

E-18 Corp. (OTCBB: ETEN), through its wholly owned subsidiary, SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), today announces completion of the US patent filing for the Protectus Safety Dental Syringe, broadening the company’s market opportunities to include the multi-billion dollar dental syringe market.

24 Sep 2009

Novel cleavage sites for enzyme caspase-3 identified

Investigators at Burnham Institute for Medical Research (Burnham) have identified novel cleavage sites for the enzyme caspase-3 (an enzyme that proteolytically cleaves target proteins). Using an advanced proteomic technique called N-terminomics, Guy Salvesen, Ph.D., professor and director of the Apoptosis and Cell Death Research program of Burnham's NCI-designated Cancer Center, and colleagues determined the cleavage sites on target proteins and found, contrary to previous understanding, that caspase-3 targets α-helices as well as unstructured loops.

22 Sep 2009

NovoStent completes enrollment for its SAMBA Stent and Delivery System trial

NovoStent Corporation, a privately held medical device company, today announced the completion of enrollment earlier this summer in the company’s European clinical trial evaluating the use of its SAMBATM Stent and Delivery System in the treatment of superficial femoral and popliteal artery disease.

19 Sep 2009

Helix Biopharma announces the closure of private placement of 6,625,000 units

Helix BioPharma Corp. (TSX, FSE: "HBP"; OTCQX: "HXBPF") today announced that it has closed its previously announced private placement of 6,625,000 units at $2.05 per unit.

9 Sep 2009

Helix Biopharma raises funds through private placement

Helix BioPharma Corp. (TSX, FSE: "HBP" / OTCQX: "HXBPF") today announced that it has accepted subscriptions for the purchase, by way of private placement, of a total of 6,625,000 units at $2.05 per unit, for gross proceeds totaling CDN$13,581,250.

4 Sep 2009

E-18 files for an international patent for its revolutionary self-sheathing medical safety syringe technology

E-18 Corp. (OTCBB:ETEN) today announced that its wholly owned subsidiary SquareOne Medical, Inc., doing business as Protectus Medical Devices ("Protectus Medical Devices"), completed an international patent filing for its revolutionary self-sheathing medical safety syringe technology, opening substantial opportunities abroad.

27 Aug 2009

Health Canada approves Anika Therapeutics' MONOVISC drug

Anika Therapeutics, Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing and repair based on hyaluronic acid (HA) technology, today announced that it has received Health Canada approval for MONOVISC™, its single injection viscosupplement approved for the treatment of osteoarthritis of the knee. Anika expects to launch MONOVISC this month through its long-term ORTHOVISC® distribution partner in Canada, Rivex Pharma Inc., the specialty drug distribution division of Aurora, Ontario-based Helix BioPharma Corp. (TSX: HBP). MONOVISC has been broadly available in the European Union since the second quarter of 2008.

21 Aug 2009

New understanding on mechanisms of DNA replication and transcription

By manipulating individual atoms in DNA and forming unique molecules, a Georgia State University researcher hopes to open new avenues in research towards better understanding the mechanisms of DNA replication and transcription, and perhaps leading to new treatments for diseases.

19 Jul 2009

New discovery on DNA repair mechanism

Researchers at Washington University School of Medicine in St. Louis have shed new light on a process that fixes breaks in the genetic material of the body's cells. Their findings could lead to ways of enhancing chemotherapy drugs that destroy cancer cells by damaging their DNA.

17 Jul 2009

Backtracking and proofreading in DNA transcription

Accuracy is essential for life, so in converting the information stored in DNA into a form in which it can be used, a high level of precision is required. Dr Tanniemola Liverpool from the University of Bristol Department of Mathematics, working with colleagues from the University of Leeds, has developed a mathematical model for how the required accuracy is achieved.

23 Jun 2009

Scientists create simple chemical system that mimics DNA

A team of Scripps Research scientists has created a new analog to DNA that assembles and disassembles itself without the need for enzymes. Because the new system comprises components that might reasonably be expected in a primordial world, the new chemical system could answer questions about how life could emerge.

13 Jun 2009

New antibiotics could come from a DNA binding compound that kills bacteria in 2 minutes

A synthetic DNA binding compound has proved surprisingly effective at binding to the DNA of bacteria and killing all the bacteria it touched within two minutes.

8 Jun 2009

Discovery of genetic link between periodontitis and heart attack

The relationship between the dental disease periodontitis and coronary heart disease (CHD) has been known for several years. Although a genetic link seemed likely, until now its existence was uncertain. Now, for the first time, scientists have discovered a genetic relationship between the two conditions, a researcher told the annual conference of the European Society of Human Genetics today (Monday 25 May).

25 May 2009